The report highlights that insulin-derived amyloidosis can mimic other injection-site reactions and should be considered when ...
MannKind closed 2025 on a high note, marked by milestones that reinforce our growth trajectory—including the acquisition of scPharmaceuticals and a record-setting fourth quarter surpassing $100 ...
Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...
Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab ...
Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Halozyme ...
Halozyme Therapeutics, Inc. today announced the Company entered into a global collaboration and exclusive license agreement ...
Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics ...
Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in systemic lupus erythematosus.
MNT speaks with three obesity medicine experts to find out more about the FDA-aproved Wegovy pill and how it's different from ...
The Brighterside of News on MSN
Antibody injections could replace slow IV drips in treating many diseases, MIT scientists find
Many patients endure hours-long infusions because antibody doses can exceed 100 milliliters, far beyond subcutaneous limits ...
The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.
Atacicept, a novel dual inhibitor of BAFF and APRIL, receives FDA Priority Review for IgA nephropathy treatment in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback